Biogennix bone grafting product cleared for expanded spine indication — 3 insights

Osteobiologics company Biogennix received FDA clearance March 5 for an expanded indication of its Agilon moldable bone grafting product.

Advertisement

Three insights:

1. Agilon is now cleared for use in posterolateral spine procedures when mixed with autograft.

2. The product features a high purity, type 1 fibrillar bovine collagen, which offers a site for cell attachment, migration, proliferation and differentiation.

3. The Irvine, Calif.-based company is accelerating national distribution of Agilon, which is available in three different sizes.

More articles on devices:
Rothman Orthopaedics surgeon to lead orthopedic oncology program
New Southeastern Spine Institute moves closer to completion
Kevin Lobo’s 8+ years as Stryker CEO: Leading 20+ acquisitions, boosting robotics & more

At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.

Register to Attend Webinar

160 ambulatory leaders just ranked the EHR as the single system most overdue for AI reinvention

Tuesday, August 11
12:00 PM - 1:00 PM CDT

Presenter: Gautam Shah, MBA, FACHDM, NextGen Healthcare

Advertisement

Next Up in Spinal Tech

Advertisement

Comments are closed.